Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 27;6(12):e13753. doi: 10.14814/phy2.13753

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Therapeutic treatment of targeted type II AEC‐injured mice with Compound 1 reduces plasma cytokine levels. DTR‐expressing mice (DTR+) were administered daily I.P. PBS or DT from day 0 through Day 14. Subsets of the DTR+:DT‐treated animals were treated by oral gavage once daily beginning on day 0 with vehicle or Compound 1 at 5.0 mg/kg. Plasma was collected on day 21 and analyzed for CCL11/eotaxin, CXCL10/IP‐10, CXCL5/LIX, and CCL5/Rantes. Data are reported as mean ± SD with individual data points shown (n = 13 for control, 22 for Compound 1 per group). ^# P ≤ 0.05 versus Control group by Student's t‐test.